Autopsy report · NCT03936933
Pharmacodynamic Study Goserelin 3.6mg Injection Administered Subcutaneously in Premenopausal Patients with Breast Cancer
Cause of deathSlow enrollment
“Low recruitment rate and number of subjects is less than required after 3 years.”
Life of this trial
- Registered 1 year 6 months before it started.
- Ran for about 4 years 3 months before it stopped.
- 6 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 3
- Sponsor
- Eurofarma Laboratorios S.A.
- Sponsor type
- Industry
- Conditions
- Breast Cancer
- Interventions
- Goserelin acetate 3.6 mg Injection; ZOLADEX® 3.6mg Injection
- Participants
- 6
- Sites
- 1
- Countries
- India
Trials that died the same way
- Cord Milking Impacts Neurodevelopmental Outcomes in Very Low Birth Weight Infants
“Subject recruitment and enrollment was low throughout the three years the study was active.” - Salvage Therapy With Chemotherapy and Natural Killer Cells in Relapsed/Refractory Paediatric T Cell Lymphoblastic Leukaemia and Lymphoma
“The low recruitment rate makes it very difficult to complete the study within a reasonable period of time.” - Level of Continuous Positive Airway Pressure (CPAP) in Preterm Infants After Extubation (L-CPAP Study)
“Difficulties in recruitment - will require longer time to achieve sample size” - Whole-body Vibration Physiotherapy in Kidney Transplantation
“Due to low recruitment rate” - Knee Nerve Cryoneurolysis and Impact on Pain After Prosthetic Surgery
“the recruitment rate is far too low despite an 18-month extension of the inclusion period”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.